Cui Peng, Jing Peihang, Liu Xiuxiu, Xu Wei
Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People's Republic of China.
Cancer Manag Res. 2020 Jul 17;12:5893-5902. doi: 10.2147/CMAR.S257299. eCollection 2020.
The expression of programmed death-ligand 1 (PD-L1) is common in various solid human cancers and it is an important therapeutic target. However, the expression pattern, clinical significance and potential mechanism of PD-L1 in hypopharyngeal squamous cell carcinoma (HSCC) are still lacking.
PD-L1 expression in HSCC tumor tissues and paired adjacent hypopharyngeal mucosal tissues was detected using immunohistochemistry assay, and the clinical significance of PD-L1 in HSCC was characterized. In vitro assays including cell viability assays, migration assays, invasion assays as well as Western blot assays were performed to illuminate the biological functions and underlying molecular mechanisms of PD-L1 in HSCC development.
PD-L1 expression was detected in HSCC samples but we found no positive expression in matched normal hypopharyngeal mucosal tissues. The levels of PD-L1 expression were significantly correlated with advanced clinical progression and poor patient survival. Multivariable analysis of Cox model showed that PD-L1 expression was an independent predictor for the prognosis of HSCC patients. Functional experiments showed that the ectopic expression of PD-L1 markedly influenced the proliferation, migration and invasion of FaDu cells in vitro. Mechanistically, investigations demonstrated that PD-L1 could promote the epithelial-mesenchymal transition of FaDu cells. Meanwhile, PD-L1 knockdown inhibited, while PD-L1 overexpression activated the Akt-mTOR signaling pathway in FaDu cells. The EMT induced by PD-L1 overexpression could be reversed by the Akt inhibitor.
In summary, the expression of PD-L1 can act as a significant biomarker for the adverse clinicopathological features and poor prognosis of patients with HSCC. PD-L1 can promote the proliferation, migration and invasion of FaDu cells and consequently enhance the aggressiveness. Moreover, PD-L1 induces EMT through AKT-mTOR signaling pathway. These suggest that PD-L1 has important tumor-intrinsic functions independent of its immunopathogenic effects.
程序性死亡配体1(PD-L1)在多种人类实体瘤中普遍表达,是一个重要的治疗靶点。然而,PD-L1在下咽鳞状细胞癌(HSCC)中的表达模式、临床意义及潜在机制仍不明确。
采用免疫组织化学法检测HSCC肿瘤组织及配对的下咽黏膜组织中PD-L1的表达,并分析其临床意义。通过体外细胞活力检测、迁移检测、侵袭检测及蛋白质免疫印迹检测等实验,阐明PD-L1在HSCC发生发展中的生物学功能及潜在分子机制。
在HSCC样本中检测到PD-L1表达,但在配对的正常下咽黏膜组织中未发现阳性表达。PD-L1表达水平与临床进展及患者生存率显著相关。Cox模型多因素分析显示,PD-L1表达是HSCC患者预后的独立预测指标。功能实验表明,异位表达PD-L1显著影响FaDu细胞的体外增殖、迁移和侵袭。机制研究表明,PD-L1可促进FaDu细胞的上皮-间质转化。同时,敲低PD-L1可抑制,而过表达PD-L1可激活FaDu细胞中的Akt-mTOR信号通路。Akt抑制剂可逆转PD-L1过表达诱导的上皮-间质转化。
综上所述,PD-L1的表达可作为HSCC患者不良临床病理特征和预后不良的重要生物标志物。PD-L1可促进FaDu细胞的增殖、迁移和侵袭,从而增强其侵袭性。此外,PD-L1通过AKT-mTOR信号通路诱导上皮-间质转化。这些表明,PD-L1具有重要的肿瘤内在功能,独立于其免疫致病作用。